AndreaLora(Lora)KosslerMDFACS
Ophthalmology • Stanford, CAOculo-Plastic & Orbital Reconstructive Surgery
Associate Professor of Ophthalmology Director, Oculofacial Plastic & Reconstructive Surgery Co-Director, Multidisciplinary Thyroid Eye Disease Center Co-Director, Orbital and Ocular Oncology Center
Dr. Kossler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Summary
- Andrea Lora Kossler, MD, is Associate Professor of Ophthalmology at Stanford University School of Medicine and Director of the Ophthalmic Plastic, Reconstructive Surgery and Orbital Oncology Service. She specializes orbital reconstructive and aesthetic facial plastic surgery. Dr. Kossler’s research interests include thyroid eye disease and orbital oncology.
Education & Training
University of Miami Hospital and ClinicsFellowship, Ophthalmic Plastic and Reconstructive Surgery, 2010 - 2012
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2007 - 2010
Mount Sinai Medical Center of FloridaInternship, Internal Medicine, 2006 - 2007
Georgetown University School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2012 - 2025
FL State Medical License 2010 - 2014- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Annual AAO Conference: Best Ocular & Orbital Oncology Paper AAO- American Academy of Ophthalmology
- Marvin Quickert Thesis Award ASOPRS- American Society of Ophthalmic Plastic & Reconstructive Surgery
- Valedictorian & Summa Cum Laude Georgetown University School of Medicine
Clinical Trials
- TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Start of enrollment: 2021 Sep 16
- A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED) Start of enrollment: 2021 Dec 03
- A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Start of enrollment: 2022 Jul 01
Publications & Presentations
PubMed
- Surgical Timing for Patients with Thyroid Eye Disease Treated with Teprotumumab: A Collaborative Multicenter Study.Hannah L Walsh, Kevin D Clauss, Benjamin I Meyer, Emanuil Parunakian, Cigdem Yasar
Ophthalmic Plastic and Reconstructive Surgery. 2024-12-10 - 1 citationsOphthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database.Lee Quiruz, Negin Yavari, Bijal Kikani, Ankur Sudhir Gupta, Karen Michelle Wai
American Journal of Ophthalmology. 2024-12-01 - Risk of Intestinal Complications, Extraintestinal Morbidity, and Mortality in Patients with Crohn's Disease and Ocular Involvement.Amer F Alsoudi, Karen M Wai, Euna Koo, Ryan A McConnell, Nathan H Pham
Ocular Immunology and Inflammation. 2024-12-01
Journal Articles
- Bilateral Atypical Eyelid Lesions in a 50-Year-Old WomanEmily S Charlson, Andrea L Kossler, JAMA Ophthalmology
Authored Content
- Vibrating Device Relieves Pain at Anesthesia Injection SitesJanuary 2020
Press Mentions
New Drug Gives Patient His Sight BackMarch 23rd, 2022- The Impact on Ocular Surface Disease of Teprotumumab for TEDNovember 23rd, 2021
Professional Memberships
- Fellow
- Member
Other Languages
- Spanish
Industry Relationships
- Consultant, Immunovant Inc
- Consultant, Horizon Therapeutics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
